SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

April 01, 2013 07:00 ET

Implant Sciences Wins Contract for Seven Quantum Sniffers to Africa

Company Continues to Expand Customer Base in Africa

WILMINGTON, MA--(Marketwire - Apr 1, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has sold seven Quantum Sniffer™ QS-H150 handheld explosives trace detectors to a new customer in Africa. The units are to be deployed for security screening at court buildings and facilities.

"With its low maintenance, easy-to-use design, the QS-H150 provides explosives trace detection for the real world. These features are consistently mentioned by customers as being the deciding factor when choosing new equipment," stated Implant Sciences' Vice President of Sales and Marketing, Darryl Jones. "Our customers, whose focus is on security at all times, continue to look to Implant Sciences and our reliable solutions that work in a wide variety of field conditions."

"This contract comes as a result of the expanded reach of our sales team. As we grow as a company, we are reaching new distributors and new customers," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "Certain regions of Africa are facing severe and urgent security threats from terrorist and criminal organizations. As our installed base of units expands in Africa, we look forward to continued growth driven by our increasing brand recognition, reputation for excellence and proven value proposition."

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector
The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the U.S. Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:
    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact